Abu Dhabi’s artificial intelligence university establishes dedicated robotics and computer science departments to meet surging global demand

MBUZAI Students

ABU DHABI, United Arab Emirates, Aug. 03, 2023 (GLOBE NEWSWIRE) — Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) has established two new departments and four associated graduate programs dedicated to robotics and computer science, catering to the surging global demand for these disciplines, which is expected to hit USD $225 billioni and $140 billion, respectively, by 2030ii.

The new departments complement the university’s existing computer vision (CV), machine learning (ML), and natural language processing (NLP) departments, which are ranked among the top 20 globally by CSRankings.

Aligned with the formation of the new departments, the university has launched master’s and Ph.D. programs in robotics and computer science. These programs will help further develop the UAE’s wider AI ecosystem and strengthen its position as an international hub for AI research and innovation.

MBZUAI President and University Professor, Eric Xing, said: “The addition of these two new departments represents MBZUAI’s lasting effort in developing a solid foundation for research excellence and innovation in artificial intelligence. The university will continue to bring into Abu Dhabi world leading faculty and researchers in the fields and to empower students to become pioneers with highly sought-after skills in developing advanced AI tools and applications across industries. Given the digital renAIssance we find ourselves in, skills in these disciplines are increasing in demand.”

The Robotics Department will focus on rigorous, high-impact, original research, emphasizing robot learning and robot algorithms rather than the development of new robot hardware. The Computer Science Department will provide unparalleled technical depth in the foundational technologies that have given rise to the phenomenal growth and impact of IT in the past four decades.

MBZUAI Acting Provost, Professor Timothy Baldwin, said: “MBZUAI is at the forefront of AI education and research, making our programs distinctive and globally competitive. The Robotics Department will focus on human-centered and autonomous robotics research, as well as the development of the next generation of robotics practitioners with deep skills in both AI and robotics, supporting careers at the cutting edge of academia, industry, and government.”

Robotics is a transformative technology, revolutionizing sectors such as manufacturing, healthcare, agriculture, and transportation. Research indicates strong demand for robotics expertise in the coming years, with the robotics technology market expected to surpass US$225.6 billion in value by 2030iii. This demand will be critically hampered by a predicted global talent shortage, with up to 85 million jobs potentially going unfilled by 2030 due to a lack of skilled people to fill themiv. Similarly, the global computer science job market is also booming, with projections of a 14.5% CAGR from 2021 to 2027 and an estimated 3.5 million jobs by 2026v.

Applications for the 2024 admissions year will open on September 1, 2023. For more information, visit mbzuai.ac.ae or contact admissions@mbzuai.ac.ae


Precedence Research
ii Precedence Research
iii Precedence Research
iv Korn Ferry
v CS job market projections (The Most Surprising Computer Science Job Statistics And Trends in 2023 • GITNUX)

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eb82e469-758c-46ca-b84c-ddeb1502171d

GlobeNewswire Distribution ID 1000833037

Zenas BioPharma annonce la publication d’une étude de phase 2 sur l’obéxélimab, un traitement expérimental pour la maladie liée aux IgG4 (ML-IgG4), dans The Lancet Rheumatology

L’étude a montré que l’obéxélimab produisait une amélioration clinique rapide, forte et soutenue, y compris une rémission clinique complète, chez la plupart des patients atteints de ML-IgG4 active

Les résultats soutiennent la poursuite du développement de l’obéxélimab pour le traitement de la ML-IgG4 et potentiellement d’autres maladies auto-immunes à médiation par les cellules B

WALTHAM, Massachusetts, 02 août 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de traitements basés sur l’immunité, annonce que The Lancet Rheumatology a publié les résultats d’une étude de phase 2 évaluant l’obéxélimab pour le traitement de patients atteints de la maladie liée aux IgG4 (ML-IgG4). Sur la base des résultats de cette étude, un essai de phase 3 chez des patients atteints de ML-IgG4 est en cours afin d’évaluer davantage l’efficacité et l’innocuité de l’obéxélimab administré par injection sous-cutanée.

La ML-IgG4 est une maladie fibro-inflammatoire chronique à médiation immunitaire qui peut toucher plusieurs organes, notamment les glandes salivaires principales, les orbites, les glandes lacrymales, le pancréas, l’arbre biliaire, les poumons, les reins et le rétropéritoine. Environ 20 000 patients sont diagnostiqués comme étant atteints d’une ML-IgG4 rien qu’aux États-Unis. Bien qu’elle soit de plus en plus reconnue, il reste nécessaire de poursuivre la recherche et de trouver des options thérapeutiques efficaces pour les personnes qui vivent avec cette maladie invalidante.

Dans le monde entier, l’utilisation de glucocorticoïdes est largement considérée comme la norme de soins pour traiter la ML-IgG4. Il n’existe aucune option de traitement approuvée pour cette condition. Bien que couramment utilisés, les glucocorticoïdes et les traitements de déplétion des cellules B disponibles conduisent rarement à des rémissions à long terme sans traitement, et sont associés à un risque élevé de toxicité chez ces patients. Ces traitements altèrent également les réponses vaccinales, y compris celles contre le SRAS-CoV-2 et la grippe.

Dans une étude pilote prospective ouverte à bras unique et centre unique visant à évaluer l’efficacité et l’innocuité de l’obéxélimab dans le traitement des patients atteints de ML-IgG4 (inscription NCT02725476 sur clinicaltrials.gov), l’obéxélimab a démontré une forte amélioration sur l’IgG4-RD Responder Index, qui mesure l’activité de la maladie, en inhibant la fonction des cellules B, sans les épuiser.

Le manuscrit publié, intitulé « Obexelimab for the Treatment of Patients with IgG4-Related Disease: An Open-Label, Single-Arm, Pilot Study to Evaluate Efficacy, Safety, and Mechanism of Action » (L’obéxélimab pour le traitement des patients atteints de maladie liée aux IgG4 : une étude pilote ouverte à bras unique visant à évaluer l’efficacité, l’innocuité et le mode d’action) est disponible en ligne et figurera dans le numéro d’août de The Lancet Rheumatology 2023;5(8) [E428-E429].

Ci-après figurent les principales conclusions du document :

  • L’obéxelimab a produit une amélioration clinique rapide, forte et soutenue, y compris une rémission complète (score de 0 sur l’IgG4-RD Responder Index), chez la plupart des patients atteints de ML-IgG4 active.
  • Lors du traitement à base d’obéxélimab, des réductions des cellules B en circulation, y compris les plasmablastes, ont été observées sans preuve de mort cellulaire.
  • Par ailleurs, une réduction des cellules B en circulation et un rapide retour à des niveaux quasi-normaux après arrêt du traitement suggèrent que l’obéxélimab pourrait mener à une séquestration des cellules B dans les organes lymphoïde ou la moelle osseuse.
  • L’obéxélimab s’est révélé bien toléré. La majorité des effets indésirables liés aux traitement étaient de grades 1 ou 2, les plus courants étant des réactions liées à la perfusion gastro-intestinale, modérées pour la plupart.

« Nos conclusions constituent un pas en avant considérable dans notre compréhension des mécanismes sous-jacents de la maladie liée aux IgG4, ouvrant la voie à des stratégies de traitement plus ciblées », a déclaré John Stone, MD, MPH, professeur de médecine à la Harvard Medical School, et de la chaire de médecine Edward A. Fox au Mass General Hospital. « Notre équipe est honorée de voir ses recherches être reconnues par The Lancet Rheumatology, et nous sommes immensément reconnaissants aux patients qui ont participé à cette étude révolutionnaire. »

À propos de l’obéxélimab

L’obéxélimab est un anticorps monoclonal, humanisé, non cytolytique, bifonctionnel et expérimental de phase 3 qui imite l’action de complexes antigène-anticorps en liant la CD19 et le FcγRIIb afin d’inhiber l’activité des cellules de lignée B. Dans plusieurs études cliniques de stade précoce pour diverses maladies auto-immunes, 198 sujets ont été traités avec l’obéxélimab. Dans le cadre de ces études cliniques, l’obéxélimab a démontré une inhibition efficace de la fonction des cellules B sans les épuiser, donnant lieu à un effet thérapeutique encourageant chez les patients atteints de diverses maladies auto-immunes. Zenas a acquis des droits mondiaux exclusifs sur l’obéxélimab auprès de Xencor, Inc.

Davantage d’informations sur l’étude de phase 3 (INDIGO) pour le traitement de la maladie liée aux IgG4 sont disponibles sur clinicaltrials.gov : NCT05662241.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients dans le monde entier. Avec un développement et des opérations cliniques à l’échelle mondiale, Zenas fait progresser un portefeuille mondial approfondi et équilibré de thérapies auto-immunes potentielles premières et meilleures de leur catégorie dans des domaines où les besoins médicaux ne sont pas satisfaits, tout en répondant aux exigences de valeur de l’environnement dynamique mondial des soins de santé. Le portefeuille de la société continue de croître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes confrontées à des maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le site www.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Contact auprès des investisseurs et des médias :
Joe Farmer, président et directeur de l’exploitation
Zenas BioPharma
IR@zenasbio.com

GlobeNewswire Distribution ID 8886118

Zenas BioPharma Publica Fase 2 do Estudo Clínico do Obexelimabe, um Tratamento Investigativo da Doença Relacionada à IgG4 (IgG4-RD), no The Lancet Rheumatology

Estudo revelou que o obexelimabe produziu melhora clínica rápida, forte e sustentada, incluindo remissão clínica completa, na maioria dos pacientes com IgG4-RD ativa

Os resultados apoiam o desenvolvimento contínuo do obexelimabe para o tratamento de IgG4-RD e potencialmente outras condições autoimunes mediadas por células B

WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias imunológicas, anunciou a publicação da Fase 2 do estudo que avalia o obexelimabe para o tratamento de pacientes com a Doença Relacionada à IgG4 (IgG4-RD) Com base nos resultados deste estudo, a Fase 3 do estudo em pacientes com IgG4-RD está em andamento para investigar ainda mais a eficácia e a segurança do obexelimabe administrado como uma injeção subcutânea.

A IgG4-RD é uma doença fibroinflamatória crônica imunomediada que pode afetar múltiplos órgãos, incluindo as principais glândulas salivares, órbitas, glândulas lacrimais, pâncreas, árvore biliar, pulmões, rins e retroperitônio. Cerca de 20.000 pacientes são diagnosticadas com IgG4-RD somente nos Estados Unidos. Apesar da crescente visibilidade da doença, ainda há necessidade de mais pesquisas e opções terapêuticas eficazes para indivíduos que vivem com essa doença debilitante.

Em todo o mundo, o uso de glicocorticoides é amplamente considerado o padrão de tratamento para o tratamento de IgG4-RD. No momento não existe nenhum tratamento aprovado para esta condição. Embora comumente usados, os glicocorticoides e as terapias de depleção de células B disponíveis raramente levam a remissões livres de tratamento a longo prazo e estão associados a um alto risco de toxicidade para os pacientes. Tais terapias também prejudicam as respostas vacinais, incluindo as do SARS-CoV-2 e da gripe.

Em um estudo piloto prospectivo, aberto, de braço único e centro único para avaliar a eficácia e a segurança do obexelimabe no tratamento de pacientes com IgG4-RD (registro clinicaltrials.gov NCT02725476), o obexelimabe demonstrou forte melhora no IgG4-RD Responder Index, uma medição da atividade da doença, inibindo a função das células B, sem esgotar as células B.

O manuscrito publicado, intitulado “Obexelimab for the Treatment of Patients with IgG4-Related Disease: An Open-Label, Single-Arm, Pilot Study to Evaluate Efficacy, Safety, and Mechanism of Action,” está disponível online e constará na edição de agosto do The Lancet Rheumatology 2023;5(8) [E428-E429].

As principais conclusões do artigo são as seguintes:

  • O Obexelimabe apresentou melhora clínica rápida, forte e sustentada, incluindo remissão completa (pontuação 0 no IgG4-RD Responder Index), na maioria dos pacientes com IgG4-RD ativa.
  • Durante o tratamento com obexelimabe, foram observadas reduções nas células B circulantes, incluindo plasmablastos, sem evidência de morte celular.
  • Além disso, a redução das células B circulantes e o rápido retorno aos níveis quase normais após a descontinuação do tratamento, sugerem que o obexelimabe pode levar ao sequestro de células B em órgãos linfoides ou na medula óssea.
  • O Obexelimabe foi bem tolerado. A maioria dos eventos adversos relacionados ao tratamento foram de grau 1 ou 2, com os eventos adversos mais comuns sendo eventos relacionados à infusão gastrointestinal, a maioria dos quais foram leves.

“Os resultados são um passo significativo na compreensão dos mecanismos subjacentes da Doença Relacionada à IgG4; abrindo caminho para estratégias de tratamento mais direcionadas”, disse John Stone, MD, MPH, Professor de Medicina da Harvard Medical School e Edward A. Fox Chair em Medicina do Mass General Hospital. “Nossa equipe tem a honra de ter nossa pesquisa reconhecida pelo The Lancet Rheumatology, e somos imensamente gratos aos pacientes que participaram deste estudo inovador.”

Sobre o Obexelimab

O obexelimabe é um anticorpo monoclonal humanizado de Fase 3 bifuncional, não citolítico, de investigação que imita a ação dos complexos antígeno-anticorpo por ligação a CD19 e FcγRIIb para inibir a atividade das células da linhagem B. Em vários estudos clínicos em fase inicial de diversas doenças autoimunes, 198 indivíduos foram tratados com obexelimabe. Nestes estudos clínicos, o obexelimabe demonstrou inibição eficaz da função das células B sem a redução das células, e um efeito encorajador no tratamento de pacientes com várias doenças autoimunes. Zenas adquire da Xencor, Inc. direitos mundiais exclusivos do obexelimabe.

Mais informações sobre a Fase 3 (INDIGO) do estudo para o tratamento de Doenças Relacionadas à IgG4 estão disponíveis em clinicaltrials.gov: NCT05662241.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial comprometida em se tornar líder global no desenvolvimento e comercialização de terapias imunológicas para pacientes em todo o mundo. Com desenvolvimento clínico e operações globais, a Zenas está avançando um portfólio global profundo e equilibrado das melhores terapêuticas autoimunes em potencial em áreas de alta necessidade médicas, atendendo aos requisitos de valor do dinâmico ambiente global de saúde. O pipeline da empresa continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Joe Farmer, Presidente e COO
Zenas BioPharma
IR@zenasbio.com

GlobeNewswire Distribution ID 8886118

AA Sports International supports 2023 Cheetah Cup

Adu Amofa (AA) Sports International donated items for the 2023 Cheetah Cup at the Cheetah FC Office at Kasoa in the Central Region.

The items were made up of bags of rice, oil, and an undisclosed amount of money.

Mr Abdul Hayye Yartey, President of Cheetah FC expressed his profound gratitude to AA Sports International management for the kind gesture.

He said, “on behalf of everyone at Cheetah Football Club, I want to express my heartfelt gratitude to AA Sports International for donating items in support of this year’s Cheetah Cup.

“I’m proud of the leadership of AA Sports International, particularly, the founder, Mark Adu Amofah for coming up with this great and innovative project.

“I’m elated with the path being charted by Mark whom I’ve known since 2000,” he noted.

He added that it was always great to see footballers and ex-footballers giving back to the sports and society.

He said, “when I was Team Manager of Fauzan FC between 2000 and 2003, he was one of the gifted and hardworking players we had and I’m proud of how his career and life have turned out.”

AA Sports International is a Non-profit registered organization that support sports with the core objective of changing lives through creating greater awareness for kids with exceptional sports abilities.

Their vision is to provide quality sports and education, awareness, mentorship, sponsorships, and development opportunities for all children regardless of gender.

Source: Ghana News Agency

Ubuntu Online Academy will give Ghanaian footballers a better life – GFA

Mr. Mark Addo, Vice President of the Ghana Football Association, says the newly introduced Ubuntu Online Academy, a project by Soccer for Dreamers will create a better future for footballers after their career.

Ubuntu Online Academy is a project by Soccer for Dreamers, a US-based Non-Governmental Organization which seeks to train footballers in skills such as entrepreneurship, interview guide, and leadership.

Speaking at the launch of the project, the Vice President said this was in line with the GFA’s mandate to give footballers better lives, having recently launched a football school which aimed at educating players in the football ecosystem.

“In terms of the GFA foundation, where we have partnered several universities to advance knowledge into capacity of ex and current footballers and also broaden their skills outside football,” he said.

He commended Soccer for Dreamers for their partnership with the GFA to give footballers a better life after retirement.

Mr. Addo urged footballers, coaches, and club administrators to take advantage of the opportunity which would help get them on the right track and broaden their knowledge on certain aspects of life.

“We have millions of Ghanaians playing football so there is a great opportunity for them to leverage this for boys and girls to access and learn basic skills”.

Madam Sylvia Akwaboah, President of Soccer for Dreamers expressed her excitement on partnering the GFA to launch the Ubuntu Online Academy, which she said was the beginning of a new era.

“Even though we already have contents, we still need contents from businesses on the continent. We need to know what they need from the youth to level up, the cooperations and the business owners are the ones who know what they need,” she appealed.

She urged the youth, most especially sportsmen and women to embrace the opportunity given them to become better people in societies.

Soccer for Dreamers was founded by three brothers Jed Akwaboah, Baruch Akwaboah and Kayden Akwaboah, with the support of their mother Madam Sylvia Akwaboah who serves as President.

The foundation seeks to help football lovers get all the needed equipment to enjoy playing, having recently provided football boots, balls, and jerseys to some clubs in Ghana.

The event was coordinated by Soccer for Dreamers country representative, Stephane Lecosson.

Source: Ghana News Agency

Prince Tagoe’s alleged fraud case adjourned to August 30

The Accra Circuit Court trying Prince Tagoe, a former Black Stars player, over an alleged USD40,000 fraud, has given the accused person time to settle the complainant with the rest of the money before August 30,2023 as requested.

The Court presided over by Mr Bright Samuel Acquah would have no option than to try the matter if the parties failed to settle the matter out of court.

It has, therefore, adjourned the case to August 30, 2023.

Tagoe is on a GH¢100,000 bail with three sureties, one of whom should be a civil servant for allegedly taking USD 40,000 from Mr George Antwi Boateng, the complainant, also a former footballer, under the pretext of supplying him with a 4X4 Lexus vehicle.

The court ordered that one of the sureties be justified with landed property.

Tagoe has denied the offence and has paid GH¢129,000 out of the USD40,000 which is equivalent to GH¢265,200 he allegedly took by false pretense.

Prosecuting, Police Detective Chief Inspector Agartha Abena Asantewaa earlier told the court that Mr Antwi Boateng, was based in Germany.

She said Tagoe, was once a player under the management of the complainant in Germany.

Detective Chief Inspector Asantewaa said in 2020, Tagoe and Boateng met in Ghana and the complainant told the accused that he needed a 4X4 Lexus vehicle to buy.

The prosecution said the accused allegedly agreed to import a vehicle for the complainant at USD40, 000 equivalent to GH¢265, 200.

She said on January 8, 2021, USD40,000 was paid into the accused person’s Bank Account with the accused acknowledging receipt through a phone call to the complainant.

The court said the accused promised to deliver the vehicle to the complainant on March 30, 2021, but failed.

Detective Chief Inspector Asantewaa said Tagoe called the complainant and pleaded for an additional two weeks to produce the vehicle and the complainant agreed.

The Court heard that the accused person was not able to import the vehicle as promised.

She said on April 27, 2021, the complainant came to Ghana to take his vehicle, but to no avail.

The prosecution said when the complainant called to demand the vehicle, the accused stated that he could not import the vehicle and that he had allegedly spent the money on some pressing issues.

Source: Ghana News Agency